KP Tissue Releases Second Quarter 2026 Financial Results

EBITDA jumps 25%, but net income stalls and market leadership claims lack proof.

What the company is saying

KP Tissue Inc. reports a 2.8% revenue increase to $550.9 million and a 25% rise in adjusted EBITDA to $90.6 million for Kruger Products in Q2 2026. The company highlights operational efficiency, particularly from its Away-From-Home business, as a driver of growth. Management, led by CEO Dino Bianco, frames the quarter as maintaining 'strong momentum,' emphasizing cost control and profitability improvements. The announcement asserts Kruger Products' market leadership in Canada and ongoing U.S. growth with the White Cloud® brand, but provides no supporting data for these claims. The tone is upbeat and forward-looking, with mention of a share recovery plan and long-term expansion via a new TAD facility in the western United States. Dividend continuity is underscored with a declared $0.21 per share payout.

What the data suggests

Revenue increased by $14.8 million (2.8%) year-over-year, reaching $550.9 million in Q2 2026. Adjusted EBITDA rose sharply by $18.1 million (25.0%) to $90.6 million, reflecting improved operating margins. Cost of sales fell by $22.1 million (4.8%), reducing its share of revenue from 86.2% to 79.9%, indicating better efficiency. SG&A expenses increased by $3.9 million (8.3%), now 9.3% of revenue versus 8.8% a year ago. Net income was flat at $22.1 million, showing that bottom-line profitability did not benefit from the operational gains. KPT’s net income was $2.5 million, and liquidity stood at $422.6 million as of June 30, 2026. The data is robust for headline financials but lacks granularity on segment or brand performance, leaving qualitative claims about market leadership and U.S. growth unsubstantiated.

Analysis

The announcement presents a positive tone, highlighting year-over-year growth in revenue and adjusted EBITDA, as well as improved cost efficiency. These claims are substantiated by disclosed numerical data, including revenue, adjusted EBITDA, net income, and cost of sales. However, net income is flat year-over-year, which tempers the strength of the operational improvements. Several qualitative statements, such as 'strong momentum' and 'heightened operational efficiency from Kruger PRO,' are not directly supported by segment-level or brand-specific data. Forward-looking statements regarding market conditions, share recovery plans, and a new TAD facility are present but do not dominate the release. The majority of the announcement is focused on realised, measurable results, but some claims about market leadership and future initiatives are aspirational or lack supporting evidence. No large capital outlay is disclosed as imminent, and the benefits of the new TAD facility are long-term and still in planning stages.

Risk flags

• ●Net income stagnation is a concern: despite a 25% EBITDA increase, net income remained flat at $22.1 million year-over-year. This suggests that gains in operational efficiency are not translating into higher bottom-line profitability, possibly due to increased SG&A or other below-EBITDA costs.
• ●Market leadership and U.S. growth claims are unsupported: the company asserts dominance in Canada and growth in the U.S. with the White Cloud® brand but provides no market share, sales, or segment data to verify these statements. Investors cannot validate these strategic claims from the disclosed numbers.
• ●Rising SG&A expenses may erode future margins: SG&A increased by 8.3% to $51.1 million, outpacing revenue growth and now representing a higher share of sales. If this trend continues, it could offset future operational gains.
• ●Forward-looking initiatives lack detail: plans for a share recovery and a new TAD facility are mentioned, but no specifics on expected financial impact, capital requirements, or execution timelines are provided. This limits visibility into the path from strategy to realised value.

Bottom line

KP Tissue Inc. delivered solid operational improvements with a 25% increase in adjusted EBITDA and a notable reduction in cost of sales, but these gains did not translate to net income growth, which stayed flat at $22.1 million. The company's upbeat narrative around market leadership and U.S. expansion is not backed by segment-level or brand-specific data, making it difficult to assess the credibility of these strategic claims. Rising SG&A costs and the absence of detail on forward-looking projects add uncertainty to the outlook. The declared $0.21 per share dividend signals stability but does not offset the lack of bottom-line progress. For investors, the most important takeaway is that while operational metrics are improving, the ultimate impact on shareholder value remains unclear until net income growth and substantiation of market positioning are demonstrated. Future disclosures should include granular segment data and concrete milestones for strategic initiatives to improve transparency and investment relevance.

Announcement summary

(TSX: KPT) KP Tissue Inc. reports Q2 2026 financial and operational results for KPT and Kruger Products Inc., with Kruger Products' revenue at $550.9 million in Q2 2026 compared to $536.1 million in Q2 2025, an increase of $14.8 million or 2.8%. Adjusted EBITDA was $90.6 million in Q2 2026 compared to $72.5 million in Q2 2025, an increase of 25.0%. Net income was unchanged at $22.1 million in Q2 2026 compared to $22.1 million in Q2 2025. KPT had net income of $2.5 million in Q2 2026. The Board of Directors of KPT declared a quarterly dividend of $0.21 per share to be paid on October 15, 2026 to shareholders of record at the close of business on September 30, 2026. Total liquidity, representing cash and availability under the revolving credit agreements, was $422.6 million as of June 30, 2026. KPT currently holds a 12.0% interest in Kruger Products.

Disagree with this article?